OPTIMIZE: 3 versus 12 months dual antiplatelet therapy after angioplasty with DES

Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared the 3 – months versus 12 months of dual antiplatelet 

after angioplasty with zotarolimus-eluting stent in real-world patients. This was a prospective, multicenter study randomized 1563 patients to receive aspirin and clopidogrel for 3 months and 1556 to receive both drugs for 12 months. The primary end point was death, myocardial infarction, stroke and major bleeding at one year. No significant difference was observed between the two groups in the incidence of the primary end point with 5.8 % events for 12 months of dual anti platelet versus 6% for three months. With these results the strategy of three months reached the noninferiority criteria. There were no differences in the incidence of stent thrombosis.

Original title: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI